Simplify High Yield ETF(CDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CDX Simplify High Yield ETF

Trading 01-16 15:30:47 EST

22.40

+0.13

+0.56%

High22.41	Low22.30	Vol469.84K
Open22.30	D1 Closing22.27	Amplitude0.48%
Mkt Cap452.94M	Tradable Cap452.94M	Total Shares20.23M
T/O10.52M	T/O Rate2.32%	Tradable Shares20.23M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CDX","market":"US","secType":"STK","nameCN":"Simplify High Yield ETF","latestPrice":22.3952,"timestamp":1768595445240,"preClose":22.27,"halted":0,"volume":469836,"delay":0,"floatShares":20225001,"shares":20225001,"eps":0,"marketStatus":"Trading","change":0.1252,"latestTime":"01-16 15:30:47 EST","open":22.3025,"high":22.41,"low":22.3025,"amount":10516702.841063999,"amplitude":0.004827,"askPrice":22.4,"askSize":150,"bidPrice":22.38,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1768597200000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":22.27,"sharesOutstanding":20225001,"nav":22.33,"aum":451723275.51,"dividendRate":0.071489,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":22.3,"preClose":22.27,"latestTime":"08:00 EST","volume":800,"amount":17840,"timestamp":1768568425604},"postHourTrading":{"tag":"盘后","latestPrice":22.27,"preClose":22.27,"latestTime":"16:10 EST","volume":12,"amount":267.24,"timestamp":1768511404171},"volumeRatio":5.8203},"requestUrl":"/m/hq/s/CDX/tweets","defaultTab":"tweets","newsList":[{"id":"2589825171","title":"Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition","url":"https://stock-news.laohu8.com/highlight/detail?id=2589825171","media":"GlobeNewswire","labels":["productRelease","conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589825171?lang=en_us&edition=fundamental","pubTime":"2025-12-06 21:05","pubTimestamp":1765026300,"startTime":"0","endTime":"0","summary":"– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as a chemotherapy-free combination approach in diffuse large B-cell lymphoma","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/06/3201049/0/en/Arvinas-Presents-Preclinical-Data-Supporting-Mechanistic-Synergies-and-Enhanced-Antitumor-Activity-with-the-Combination-of-ARV-393-and-Glofitamab-at-the-2025-American-Society-of-He.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B66KJ199.SGD","IE00B7SZL793.SGD","TGI","IE00B19Z4B17.USD","AFG","BK4107","IE0031619046.USD","BK4187","CDX","BK4117"],"gpt_icon":0},{"id":"2583886845","title":"Press Release: BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2583886845","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583886845?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:05","pubTimestamp":1762981500,"startTime":"0","endTime":"0","summary":"-- BBOT debuted as a publicly traded company focused on optimized target. coverage for patients with tumors driven by RAS and PI3K<ALPHA> and a. synergistic portfolio that is designed to enable targeted KRAS. -- Advanced three ongoing Phase 1 clinical trials, with clinical data. -- Cash runway expected to fund BBOT operations into 2028. -- Appointed industry veteran Uneek Mehra as Chief Financial Officer. \"The third quarter marked an exciting period for BBOT as we made our debut on Nasdaq and welcomed industry veteran Uneek Mehra as our Chief Financial Officer,\" said Eli Wallace, PhD, Chief Executive Officer of BBOT. \"We continue to advance a robust pipeline of next-generation KRAS and PI3K<ALPHA> inhibitors designed to target the RAS pathway, which is one of the most commonly dysregulated in oncology. With three internally discovered clinical assets progressing toward key data readouts in 2026 and a strong financial position expected to fund operations into 2028, we are well positione","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBOT","BK4139","PRGS","LU2065732104.USD","CDX","BK4097","NQmain"],"gpt_icon":0},{"id":"2579172541","title":"Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition","url":"https://stock-news.laohu8.com/highlight/detail?id=2579172541","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579172541?lang=en_us&edition=fundamental","pubTime":"2025-10-31 04:01","pubTimestamp":1761854460,"startTime":"0","endTime":"0","summary":"--Data from Phase 1 Study in healthy volunteers presented at CIA Biennial Symposium-- HAMPTON, N.J., Oct.  30, 2025  (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced todaypositive data from the ong","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/30/3177884/24180/en/Celldex-Announces-Initial-Positive-Results-from-Phase-1-Trial-of-CDX-622-Demonstrating-Favorable-Safety-and-PK-Profile-and-Sustained-Mast-Cell-Inhibition.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDX","PK"],"gpt_icon":0},{"id":"2578509376","title":"Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2578509376","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578509376?lang=en_us&edition=fundamental","pubTime":"2025-10-26 00:30","pubTimestamp":1761409800,"startTime":"0","endTime":"0","summary":"Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT signaling in tumor cells without affecting glucose metabolismRobust monotherapy activity, as well as combi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/25/3174172/0/en/Preclinical-Data-Presented-at-the-2025-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics-Support-Potential-of-BBO-10203-a-First-in-Class-RAS-PI3K.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0264606111.USD","BK1184","BK4539","GEM","PDX","LU0572939691.SGD","BK1584","BK1550","01336","BK4202","LENZ","BK4007","LU0572940350.SGD","BK4139","NCI","CDX"],"gpt_icon":0},{"id":"2570045105","title":"Want To Ride The Private Credit Boom? Simplify's New ETF Is Built For It","url":"https://stock-news.laohu8.com/highlight/detail?id=2570045105","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570045105?lang=en_us&edition=fundamental","pubTime":"2025-09-26 02:54","pubTimestamp":1758826440,"startTime":"0","endTime":"0","summary":"Simplify Asset Management launched the Simplify VettaFi Private Credit Strategy ETF (NYSE: PCR), tapping into one of the most talked-about themes in 2025: private credit.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/09/25/ETFs.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/09/25/ETFs.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/etfs/new-etfs/25/09/47875681/want-to-ride-the-private-credit-boom-simplifys-new-etf-is-built-for-it","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/etfs/new-etfs/25/09/47875681/want-to-ride-the-private-credit-boom-simplifys-new-etf-is-built-for-it","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4585","BK4588","FDN","CDX","BK4550"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.0071},{"period":"3month","weight":-0.0262},{"period":"6month","weight":-0.0284},{"period":"1year","weight":0.0054},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0419},{"period":"6month","weight":0.103},{"period":"1year","weight":0.1678},{"period":"ytd","weight":0.0151}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"The adviser seeks to achieve the fund’s investment objective by investing in high yield bonds also known as “junk bonds” primarily by purchasing exchange traded funds and applying a credit hedge derivatives strategy to the fund’s investments. Under normal circumstances, the fund will invest at least 80% of its net assets in high yield securities. The fund may invest up to 20% of its portfolio in derivatives.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.009474},{"month":2,"riseRate":0.666667,"avgChangeRate":0.004695},{"month":3,"riseRate":0.5,"avgChangeRate":0.001552},{"month":4,"riseRate":0.25,"avgChangeRate":-0.011246},{"month":5,"riseRate":0.5,"avgChangeRate":0.001937},{"month":6,"riseRate":0.5,"avgChangeRate":-0.011876},{"month":7,"riseRate":0.5,"avgChangeRate":0.014283},{"month":8,"riseRate":0.5,"avgChangeRate":-0.009243},{"month":9,"riseRate":0.25,"avgChangeRate":-0.005778},{"month":10,"riseRate":0.25,"avgChangeRate":-0.009992},{"month":11,"riseRate":0.75,"avgChangeRate":0.017992},{"month":12,"riseRate":0.25,"avgChangeRate":-0.028304}],"exchange":"ARCA","name":"Simplify High Yield ETF","nameEN":"Simplify High Yield ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Simplify High Yield ETF(CDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Simplify High Yield ETF(CDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Simplify High Yield ETF,CDX,Simplify High Yield ETF股票,Simplify High Yield ETF股票老虎,Simplify High Yield ETF股票老虎国际,Simplify High Yield ETF行情,Simplify High Yield ETF股票行情,Simplify High Yield ETF股价,Simplify High Yield ETF股市,Simplify High Yield ETF股票价格,Simplify High Yield ETF股票交易,Simplify High Yield ETF股票购买,Simplify High Yield ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Simplify High Yield ETF(CDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Simplify High Yield ETF(CDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction